Genetics

male doctor wearing scrubs

What are the top NASDAQ genetics stocks year-to-date? We run through the five biggest gainers seen in 2022.

Click here to read the previous top NASDAQ genetics stocks article.

The genetics sector supports every other life science industry in a variety of ways.

One of its major contributions is the discovery of new genetic drivers of diseases. Genetic testing has grown substantially over the last few years thanks to advances in technology; growth has also been spurred by an increase in chronic diseases and the development of test kits for therapeutic areas with unmet medical needs.

Gene therapy is also a huge driver of growth in the overarching genetics market. It’s estimated that in 2020 this market was worth US$970.5 million, and it is expected to reach US$3.4 billion by 2027, growing at a compound annual growth rate of 19.5 percent over that time.


This important sector of the life science market is focused on how genes treat or prevent serious conditions in patients. This includes the potential for healthcare professionals to implement gene therapy at the cellular level instead of using medication or surgery, replacing “faulty” genes with new ones to potentially cure diseases.

Pharma and biotech companies often dabble in the genetics industry along with their core disciplines, meaning that some of the top NASDAQ genetics stocks may also have operations in other areas. For interested investors, the top NASDAQ genetics stocks listed below have products related to gene therapy, genetic testing, genetically defined cancers, and rare genetic diseases.

Data for this list was collected on July 15, 2022, using TradingView’s stock screener, and the top NASDAQ genetics stocks are listed in order of best year-to-date performance gains.

1. Voyager Therapeutics (NASDAQ:VYGR)

Year-to-date gain: 143.26 percent; market cap: US$258.04 million

Voyager Therapeutics is advancing early stage programs using its proprietary adeno-associated virus (AAV) capsids to develop gene therapies for central nervous system and other diseases. Its pipeline includes gene therapies for Huntington’s Disease, monogenic ALS, spinal muscular atrophy, GBA1 mutations and HER1+ brain metastases.

Voyager recently inked an agreement to give Novartis (NYSE:NVS) “options to license novel AAV capsids generated from Voyager’s RNA-driven TRACERTM capsid discovery platform for potential use with three undisclosed CNS targets and options to access capsids for two additional targets to be agreed on in the future.”

This NASDAQ genetics stock spiked to its highest point in 2022 on April 20, hitting C$10.60.

2. ProPhase Labs (NASDAQ:PRPH)

Year-to-date gain: 126.58 percent; market cap: US$212.77 million

ProPhase Labs is a diagnostics and genomics company leveraging its CLIA-accredited lab services to provide whole genome sequencing and research directly to consumers. ProPhase is also building a genomics data base for further research. The company’s wholly-owned subsidiary ProPhase Precision Medicine, Inc. focuses on genomics testing technologies that help to identify inherited disorders, predict disease risk, identify expected drug response, and characterize genetic mutations.

ProPhase Labs made two big announcements in June which greatly boosted its share price. These include partnering with widely recognized healthcare diagnostics companies as part of the company’s plan to significantly expand its in-house clinical testing capabilities; and the formation of wholly-owned subsidiary ProPhase BioPharma, Inc. for the licensing and development of novel drugs, compounds and biotechnology.

This NASDAQ genetics stock spiked to its highest point in 2022 on July 11, hitting C$15.25.

3. Biomea Fusion (NASDAQ:BMEA)

Year-to-date gain: 58.06 percent; market cap: US$343.89 million

Clinical stage biopharmaceutical company Biomea Fusion’s focus is on the discovery and development of covalent small molecules to treat patients with genetically defined cancers and metabolic diseases. The company’s proprietary FUSION™ System is the basis of its pipeline of covalent-binding therapeutic agents targeting cancer and metabolic diseases. These synthetic compounds offer potential advantages over conventional drugs.

In early summer, this NASDAQ genetics stock spiked to its highest point in 2022 on July 15, hitting C$12.06. The share price increase followed the presentation of positive clinical data showing the potential for the company’s covalent menin inhibitor BMF-219 as an oral, long-acting treatment for Type 2 Diabetes; and progress in the company’s Phase I clinical trial evaluating BMF-219, a covalent menin inhibitor aimed at patients with relapsed/refractory (R/R) multiple myeloma, R/R diffuse large B-cell lymphoma and R/R acute leukemias.

4. Turning Point Therapeutics (NASDAQ:TPTX)

Year-to-date gain: 64.39 percent; market cap: US$834.21 million

Clinical-stage precision oncology company, Turning Point Therapeutics has developed a pipeline of investigational precision oncology drug candidates which are being studied across a variety of solid tumors. The company's lead drug candidate is repotrectinib, a next-generation kinase inhibitor targeting the non-small cell lung cancer and advanced solid tumors in adult and pediatric patients.

Turning Point Therapeutics’ biggest news in 2022 is that the company is merging with pharmaceutical giant Bristol Myers Squibb (NYSE:BMY). The deal is expected to close during Q3 2022.

Shares of Turning Point Therapeutics peaked at C$75.38 on July 8.

5. Mirum Pharmaceuticals (NASDAQ:MIRM)

Year-to-date gain: 53.5 percent; market cap: US$758.27 million

Mirum Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of a late-stage pipeline of novel therapies targeting rare diseases, including liver diseases. The company’s LIVMARLI (maralixibat) is an oral solution that is approved in the US for the treatment of cholestatic pruritus in child and adult patients with Alagille syndrome. Mirum has submitted a marketing authorization application to the European Medicines Agency for maralixibat. Additionally, the company has two other late-stage investigational treatments for debilitating liver diseases affecting both children and adults.

In March, Mirum reported net product revenue of US$3.1 million for the first quarter of maralixibat's launch at the end of 2021, contributing to the total company revenue of US$19.1 million for the year. The firm expects at least US$8 million in maralixibat net product sales in Q1 2022.

Shares of Mirum Pharmaceuticals peaked at C$28.65 on April 11.

Don’t forget to follow us @INN_LifeScience for real-time news updates!

Securities Disclosure: I, Melissa Pistilli, hold no direct investment interest in any company mentioned in this article.

MARKETS

Markets
TSX19578.30-90.87
TSXV663.83-4.45
DOW32774.41-58.13
S&P 5004122.47-17.59
NASD12493.93-150.53
ASX7029.80+9.20

COMMODITIES

Commodities
Gold1794.13+0.15
Silver20.48-0.02
Copper3.57-0.02
Palladium2224.50+11.50
Platinum935.50+0.50
Oil90.27-0.23
Heating Oil3.35+0.02
Natural Gas7.82-0.01

DOWNLOAD FREE REPORTS

×